To further investigate which signatures of immune response are promoted by EGFR inhibition, gene set enrichment analysis (GSEA) was performed comparing all tumours undergoing EGFR inhibition (namely, erlotinib monotherapy and aPD-1 + erlotinib) against vehicle and aPD-1 tumours. This evidence concerns the gene EGFR and neoplasm.